These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19838738)

  • 41. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
    ; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Goodman WG; Herzog CA; Kubo Y; London GM; Mahaffey KW; Mix TC; Moe SM; Trotman ML; Wheeler DC; Parfrey PS
    N Engl J Med; 2012 Dec; 367(26):2482-94. PubMed ID: 23121374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
    Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
    Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.
    Muscheites J; Wigger M; Drueckler E; Fischer DC; Kundt G; Haffner D
    Pediatr Nephrol; 2008 Oct; 23(10):1823-9. PubMed ID: 18504621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
    Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cinacalcet cost and utility in dialysis patients.
    Cohen E; Uribarri J
    Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
    [No Abstract]   [Full Text] [Related]  

  • 47. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
    Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
    Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
    Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
    Charytan C; Coburn JW; Chonchol M; Herman J; Lien YH; Liu W; Klassen PS; McCary LC; Pichette V
    Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.
    Nowack R; Wachtler P
    Clin Lab; 2006; 52(11-12):583-7. PubMed ID: 17175888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical experience with cinacalcet HCl.
    Ureña Torres P
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years
.
    Joseph C; Shah S; Geer J; Juarez-Calderon M; Srivaths PR; Swartz SJ
    Clin Nephrol; 2019 Dec; 92(6):279-286. PubMed ID: 31587754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study.
    St Peter WL; Yusuf AA; Do T; Lowe KA; Liu J; Nieman KM; Bradbury BD; Collins AJ
    BMC Nephrol; 2015 Mar; 16():41. PubMed ID: 25886282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
    Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
    Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
    Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H; Fukagawa M;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.